Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
Author: Razavi, H
Waked, I
Sarrazin, C
Myers, RP
Idilman, R
Calinas, F
Vogel, W
Correa, MCM
Hezode, C
Lazaro, P
Akarca, U
Aleman, S
Balik, I
Berg, T
Bihl, F
Bilodeau, M
Blasco, AJ
Mello, CEB
Bruggmann, P
Buti, M
Calleja, JL
Cheinquer, H
Christensen, PB
Clausen, M
Coelho, HSM
Cramp, ME
Dore, GJ
Doss, W
Duberg, AS
El-Sayed, MH
Ergor, G
Esmat, G
Falconer, K
Felix, J
Ferraz, MLG
Ferreira, PR
Frankova, S
Garcia-Samaniego, J
Gerstoft, J
Giria, JA
Goncales, FL
Gower, E
Gschwantler, M
Pessoa, MG
Hindman, SJ
Hofer, H
Husa, P
Kaberg, M
Kaita, KDE
Kautz, A
Kaymakoglu, S
Krajden, M
Krarup, H
Laleman, W
Lavanchy, D
Marinho, RT
Marotta, P
Mauss, S
Moreno, C
Murphy, K
Negro, F
Nemecek, V
Ormeci, N
Ovrehus, ALH
Parkes, J
Pasini, K
Peltekian, KM
Ramji, A
Reis, N
Roberts, SK
Rosenberg, WM
Roudot-Thoraval, F
Ryder, SD
Sarmento-Castro, R
Semela, D
Sherman, M
Shiha, GE
Sievert, W
Sperl, J
Starkel, P
Stauber, RE
Thompson, AJ
Urbanek, P
Van Damme, P
van Thiel, I
Van Vlierberghe, H
Vandijck, D
Wedemeyer, H
Weis, N
Wiegand, J
Yosry, A
Zekry, A
Cornberg, M
Mullhaupt, B
Estes, C
Abstract: The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
Subject: HCV
hepatitis C
disease burden
Country: EUA
Editor: Wiley-blackwell
Rights: fechado
Identifier DOI: 10.1111/jvh.12248
Date Issue: 2014
Appears in Collections:Artigos e Materiais de Revistas Científicas - Unicamp

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.